Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Eclipse Surgical Technologies, Inc.

This article was originally published in The Gray Sheet

Executive Summary

Company elects to bypass pursuit of an expanded indication for the Eclipse TMR 2000 transmyocardial revascularization solid-state laser system for use in conjunction with coronary artery bypass grafting following a review of its regulatory strategy, announced March 15. The device was approved for TMR alone in February 1999 (1"The Gray Sheet" Feb. 15, 1999, p. 3). "FDA approved labeling is adequate," Eclipse says, and "the physician can best decide how to use the laser system within the approved labeling." A 263-patient randomized study published in the March issue of the Journal of Thoracic and Cardiovascular Surgery comparing the combination therapy to CABG alone showed "angina relief and exercise treadmill improvement were indistinguishable between groups at 12 months of follow-up"

You may also be interested in...



Eclipse Surgical TMR Laser Shipments Commence Following FDA Approval

Shipments of Eclipse Surgical Technologies' Eclipse 2000 transmyocardial revascularization laser system began "immediately" following FDA approval, announced Feb. 11, at a price of $295,000 each, according to the firm.

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT013109

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel